Charles River Labs to Exit Drug Discovery with IQVIA Asset Sale
Charles River Labs has agreed to sell its drug discovery assets to IQVIA, marking its exit from preclinical discovery services. The transaction realigns CRL’s portfolio toward core in vivo research operations and is anticipated to close in mid-2026 pending regulatory approval.
1. Transaction Details
Charles River Labs will divest its drug discovery assets to IQVIA under an agreement finalized in early 2026. The sale covers CRL’s medicinal chemistry and discovery biology units and is subject to customary regulatory clearances.
2. Strategic Focus Shift
By exiting the discovery segment, CRL sharpens its focus on in vivo preclinical research and safety assessment services. Management expects the move to improve operational efficiency and free up resources for its core laboratory offerings.
3. Expected Financial Impact
Proceeds from the transaction will bolster CRL’s balance sheet, with plans to reduce debt and potentially return capital to shareholders. The asset sale could also streamline earnings volatility by narrowing CRL’s service portfolio.